Results 11 to 20 of about 275,929 (307)

Challenges and developments in universal vaccine design against SARS-CoV-2 variants

npj Vaccines, 2022
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) had become a global concern because of its unexpectedly high pathogenicity and transmissibility.
Fangxin Zhao, Xiaodong Zai, Zhiling Zhang, Junjie Xu, Wei Chen   +4 more
doaj   +1 more source

A Polysaccharide-RBD-Fc-Conjugated COVID-19 Vaccine, SCTV01A, Showed High Immunogenicity and Low Toxicity in Animal Models

Vaccines, 2023
We previously developed a polysaccharide-–RBD-conjugated nanoparticle vaccine which induced protective efficacy against SARS-CoV-2 in a mouse model. Here, we newly developed a vaccine, SCTV01A, by chemically conjugating recombinant SARS-CoV-2 RBD-Fc and ...
Chunyun Sun, Desheng Kong, Erhong Guo, Jun Zhao, Jilei Jia, Rui Wang, Juan Ma, Meng Chen, Jianbo Lu, Chulin Yu, Kuokuo Li, Liangzhi Xie   +11 more
doaj   +1 more source

Construction and Immunological Evaluation of an Adenoviral Vector-Based Vaccine Candidate for Lassa Fever

Viruses, 2021
Lassa virus (LASV) is a rodent-borne arenavirus circulating in West African regions that causes Lassa fever (LF). LF is normally asymptomatic at the initial infection stage, but can progress to severe disease with multiorgan collapse and hemorrhagic ...
Meirong Wang, Ruihua Li, Yaohui Li, Changming Yu, Xiangyang Chi, Shipo Wu, Shulin Liu, Junjie Xu, Wei Chen   +8 more
doaj   +1 more source

Antibody Engineering for Pursuing a Healthier Future. [PDF]

Front Microbiol, 2017
Saeed AF, Wang R, Ling S, Wang S.
europepmc   +2 more sources

The Role of Antibody-Based Therapies in Neuro-Oncology

, 2023
This review explores the evolving landscape of antibody-based therapies in neuro-oncology, in particular, immune checkpoint inhibitors and immunomodulatory antibodies.
Jing Sun, Tarun Ramesh, Elizabeth R. Gerstner, Matthew A. Gaffey, Rishab Ramapriyan, Leland G. Richardson, Patrick C. Gedeon, William T. Curry, Bryan D. Choi, Annabel Curry   +9 more
core   +1 more source

Antibody Engineering

Microbiology Spectrum, 2014
ABSTRACTAdvanced molecular biology techniques developed during the past few decades have allowed the industry to exploit and commercialize the natural defense mechanisms that antibodies provide. This review discusses the latest advances in antibody-engineering technologies to enhance clinical efficacy and outcomes.
Kin-Ming, Lo, Olivier, Leger, Björn, Hock   +2 more
openaire   +3 more sources

An integrated mammalian library approach for optimization and enhanced microfluidics-assisted antibody hit discovery

Artificial Cells, Nanomedicine, and Biotechnology, 2023
Recent years have seen the development of a variety of mammalian library approaches for display and secretion mode. Advantages include library approaches for engineering, preservation of precious immune repertoires and their repeated interrogation, as ...
Ramona Gaa, Kavita Kumari, Hannah Melina Mayer, Desislava Yanakieva, Shang-Pu Tsai, Saurabh Joshi, Ralf Guenther, Achim Doerner   +7 more
doaj   +1 more source

Experimental and In Silico Modelling Analyses of the Gene Expression Pathway for Recombinant Antibody and By-Product Production in NS0 Cell Lines [PDF]

, 2012
Monoclonal antibodies are commercially important, high value biotherapeutic drugs used in the treatment of a variety of diseases. These complex molecules consist of two heavy chain and two light chain polypeptides covalently linked by disulphide bonds ...
Martin, Elaine B., C Mark Smales, Sarah K. Spurgeon (128819), Mead, Emma J., Emma J. Mead (128810), Smales, C. Mark, Chiverton, Lesley M., Smales, Christopher Mark, Elaine B. Martin (128823), C. Mark Smales (128831), Spurgeon Sarah K., Spurgeon, Sarah K., Montague, Gary A.; id_orcid, Montague, Gary A, Smales C. Mark, Montague, Gary A., von der Haar Tobias, Smales, C Mark, Emma J Mead, Sarah K Spurgeon, Gary A Montague, Martin Elaine B., Gary A. Montague (128826), von der Haar, Tobias, Mead, Emma J, Lesley M. Chiverton (128814), Chiverton Lesley M., Elaine B Martin, Tobias von der Haar, Tobias von der Haar (80575), Mead Emma J., Montague Gary A., Lesley M Chiverton   +32 more
core   +1 more source

Complement Activation by an Anti-Dengue/Zika Antibody with Impaired Fcγ Receptor Binding Provides Strong Efficacy and Abrogates Risk of Antibody-Dependent Enhancement

, 2023
To combat infectious diseases, vaccines are considered the best prophylactic strategy for a wide range of the population, but even when vaccines are effective, the administration of therapeutic antibodies against viruses could provide further treatment ...
Takeru Nambu, Ying Xiu Toh, Junichi Nezu, Christine Xing’er Koo, Frannie Jiuyi Teo, Adrian Ho, Fariyal Ahmed, Katja Fink, Siok Wan Gan, Kiyofumi Honda, Zenjiro Sampei, Tomoyuki Igawa, Cheng-I Wang, Taku Fukuzawa   +13 more
core   +1 more source

A comprehensive proteogenomic study of the human Brucella vaccine strain 104 M

BMC Genomics, 2017
Background Brucella spp. are Gram-negative, facultative intracellular pathogens that cause brucellosis in both humans and animals. The B. abortus vaccine strain 104 M is the only vaccine available in China for the prevention of brucellosis in humans ...
Xiaodong Zai, Qiaoling Yang, Kun Liu, Ruihua Li, Mengying Qian, Taoran Zhao, Yaohui Li, Ying Yin, Dayong Dong, Ling Fu, Shanhu Li, Junjie Xu, Wei Chen   +12 more
doaj   +1 more source